Remdesivir, an antiviral drug, reduces recovery time in patients with coronavirus, according to the complete results of a study published Friday night, three weeks after America's leading infectious disease expert said the study showed that the drug has "clear" benefits.
The full results of the survey, conducted by the US government agency, the National Institute of Allergy and Infectious Diseases (NIAID), were published by the leading medical journal of the New England Journal of Medicine.
The United States authorized the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suit.
The study found that remdesivir, injected intravenously daily for 10 days, accelerated the recovery of patients hospitalized with COVID-19 compared to a placebo in clinical trials in just over 1,000 patients in 10 countries.
On April 29, NIAID director Anthony Fauci, who became the trusted face of the U.S. government in the coronavirus pandemic, said preliminary evidence indicates that remdesivir had "a clear, significant and positive effect in decreasing time. recovery".
The National Institutes of Health, of which NIAID is a part, said on Friday in an online statement that researchers found that "remdesivir was more beneficial for hospitalized patients with serious illnesses who needed supplemental oxygen".
But the trial authors wrote that the drug did not prevent all deaths.
"Given the high mortality, despite the use of remdesivir, it is clear that treatment with an antiviral drug alone will probably not be enough," they said.
About 7.1% of patients who received remdesivir in the experimental group died within 14 days – compared with 11.9% in the placebo group.
However, the result is just below the threshold of statistical reliability, which means that it may be a fluke, not the ability of the drug.